U.S., Dec. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07309770) titled 'Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies' on Sept. 28.
Brief Summary: This study is a single-center, multi-cohort, phase II clinical trial. Eligible patients with HER2-positive advanced solid tumors were enrolled after providing informed consent. A total of 90 patients were allocated into three cohorts (30 patients each): those with Extramammary Paget's Disease (EMPD), rare solid tumors, or urothelial carcinoma, who had experienced failure of standard treatment or for whom no standard treatment was available. The participant recruitment period was 12 months, and the follow-up duration was 12 mo...